QuidelOrtho Corporation
QDELHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeQuidelOrtho Corporation provides diagnostic testing solutions. Valued at $891.3M, QDEL is a small-cap name in its sector. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Market Cap
$891.3M
Beta
0.74
P/E (TTM)
—
P/E (Fwd)
5.35
EPS (TTM)
$-17.85
EPS (Fwd)
$2.44
ROE
-50.0%
ROA
0.5%
Cash
$140.4M
Total Debt
$2.87B
Free CF
$208.6M
52W Change
-57.4%
Annual Financials
Cash vs Debt
QuidelOrtho Corporation carries $2.87B in total debt against $140.4M in cash reserves — debt is roughly 20.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $208.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -50.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.5% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $3.27B (2022) to $2.73B (2025), a 16% decline worth watching.
QuidelOrtho Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for QuidelOrtho Corporation and its sector.